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Erectile dysfunction following radical prostatectomy remains a frequent problem despite the development of nerve-sparing
techniques. This erectile dysfunction is believed to be neurogenic, enhanced by hypoxia-induced structural changes which result
in additional veno-occlusive dysfunction. Recently, daily use of intracavernous vasoactive substances and oral use of PDE5-
inhibitors have been clinically studied for treatment of postprostatectomy erectile dysfunction. Since these studies showed benefits
of “penile rehabilitation therapy,” these effects have been studied in a preclinical setting. We reviewed experimental literature
on erectile tissue preserving and neuroregenerative treatment strategies, and found that preservation of the erectile tissue by
the use of intracavernous nitric oxide donors or vasoactive substances, oral PDE5-inhibitors, and hyperbaric oxygen therapy
improved erectile function by antifibrotic effects and preservation of smooth muscle. Furthermore, neuroregenerative strategies
using neuroimmunophilin ligands, neurotrophins, growth factors, and stem cell therapy show improved erectile function by
preservation of NOS-containing nerve fibers.
Copyright © 2008 M. Albersen et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Cancer of the prostate is now recognized as one of the
principal medical problems in the male population [1].
At present, radical prostatectomy (RP), either retropubic,
perineal, laparoscopic, or robot-assisted laparoscopic, is the
treatment of choice in young men with clinically localised
prostate cancer. Since prostate cancer is detected at increas-
ingly younger age and lower stage, patients undergoing
radical prostatectomy generally have good baseline erectile
function, and have high expectations concerning the preser-
vation of erectile function following the procedure. Since
Walsh and Donker published their insights in the etiology
and prevention of impotence following retropubic RP in
1982, the nerve-sparing technique they described is widely
employed to improve postoperative erectile function [2, 3].
Literature research reveals widely disparate potency rates
between various studies concerning nerve-sparing RP (6–
86%) [4–12]. Despite the development of new techniques
for preservation of the cavernous nerves, many men con-
tinue to suffer from erectile dysfunction (ED) and penile
shortening after RP, due to neuropraxia. In 1997, Montorsi
and colleagues introduced the concept of early postopera-
tive vasoactive therapy and penile rehabilitation, and they
suggested that the early postoperative use of intracavernosal
injection therapy to promote penile erection may result in
improved erectile function outcomes [13]. More recently,
PDE-5-inhibitors have been studied for their use in penile
rehabilitation [14, 15]. Good results have been achieved with
the use of nerve grafts in nonnerve sparing surgery, and
the use of neuroregenerative tubular implants [16, 17]. This
review article attempts to summarize the contemporary basic
scientific knowledge on the pathophysiological mechanisms
of post-RP ED and to review current basic science evidence
for medicinal, nonchirurgical penile rehabilitation therapy
and neuroregenerative therapies.
2. ANATOMY AND PHYSIOLOGY OF THE ERECTION
The penile corpora cavernosa and the corpus spongiosum
are innervated by the combined sympathetic and parasym-
pathetic cavernous nerves (CNs), which arise from the pelvic
plexus. These nerves are condensed in the neurovascular
bundles (NVBs), which can be found in close relation to
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the dorsolateral side of the prostatic capsula and urethra,
although recent findings suggest that a significant number of
nerves can be found along the ventral parts of the prostatic
capsula (i.e., “outside” the classic NVB) [18–20]. Nitric
oxide (NO), released during nonadrenergic, noncholinergic
(NANC) stimulation from the CN terminals and from the
endothelium is the principal neurotransmitter mediating
penile erection. NO activates guanylyl cyclase, an enzyme
that raises the intracellular concentration of cyclic guanosine
monophosphate (cGMP), leading to activation of cGMP
specific protein kinases which activate further intracellu-
lar events, eventually leading to reduction of intracellular
calcium, and relaxation of the smooth muscle. cGMP is
hydrolysedto GMP by phosphodiesterase type 5 during
return to the flaccid state. The vasodilator prostaglandin
E1 (PGE1) also causes SM relaxation but by increasing
the concentration of the cyclic adenosine monophosphate
(cAMP), via stimulation of adenylate cyclase. The resulting
vasodilation results in an increase in penile blood flow.
During this phase of tumescence, relaxation of the trabecular
smooth muscle increases the compliance of the sinusoids,
resulting in expansion of the sinusoidal system. The subtuni-
cal venous plexusesare thus compressed between the expand-
ing sinusoidal wall and the noncompliant tunica albuginea,
resulting in almost total subtunical venous occlusion. These
events, augmented by contraction of the ischiocavernosus
muscles, trap the blood within the corpora cavernosa,
with an intracavernous pressure that can approach several
hundreds of mm Hg [21–24].
3. PATHOPHYSIOLOGIC MECHANISMS OF
ERECTILE DYSFUNCTION FOLLOWING
RADICAL PROSTATECTOMY
3.1. Impairment in corpus cavernosum oxygenation
3.1.1. Physiological changes in penile oxygen tension
Azadzoi and colleagues showed in a canine model that
subtunical oxygen tension in the flaccid penis was close
to 100mmHg, consistent with a largely arterial circulation,
whereas deep cavernosal oxygen tension measurements
showed an oxygen tension consistent with venous blood
flow. With pelvic nerve stimulation or injection of vasoactive
agents, oxygen tension deep within the corpus cavernosum
increased during penile erection from a level consistent with
venous blood to a level consistent with arterial blood. Also,
due to the increase of intracavernosal pressure, blood flow
in the subtunical blood flow significantly decreased [25].
Various investigators state that a persistent flaccid state of
the penis, as seen after cavernous neurotomy with absence of
nocturnal erections, causes a relatively hypoxic state causing
a variety of structural and functional changes in the corpora
cavernosa.
3.1.2. Nocturnal penile tumescence (NPT)
Nocturnal penile tumescence is a sleep-related phenomenon
that occurs during the rapid eye movement sleep-phase in
men without erectile dysfunction. These nocturnal erections
occur 3–5 times per night, lasting 30–45 minutes [26].
During these phases of NPT, arterial oxygen is supplied to
the cavernous tissue. This supply of oxygen is necessary for
the formation of NO by nitric oxide synthase (NOS) in
the cavernosal endothelium (eNOS) and in the CN endings
(nNOS). Upon its release, NO diffuses locally into smooth
muscle cells and binds with its physiologic receptor, soluble
guanylyl cyclase, which catalyses the conversion of GTP to
cGMP. This second messenger eventually evokes a decline in
cytosolic calcium resulting in smooth muscle relaxation and
penile tumescence [20, 24]. Bannowsky et al. showed absence
of NPT in a control group without nerve-sparing versus 97%
NPT in the group that underwent nerve sparing RP [27].
This absence of NPT following cavernous neurotomy causes
a permanent lack of free oxygen in the corpus cavernosum,
resulting in a predisposition to cavernosal fibrosis [19,
28]. In a rat model, this neurotomy-induced hypoxia was
demonstated by significantly higher protein expression and
immunohistochemical staining of hypoxia-inducible factor-
1α (HIF-1α) in the neurotomised rat [28]. HIF-1α is a
transcription factor that is expressed when mammalian
cells are subjected to hypoxia. This cytokine activates the
transcription of genes encoding proteins that are important
for maintaining oxygen homeostasis. This finding confirms
the theory that hypoxia of rat penes after iatrogenic nerve
injury was induced by the loss of nocturnal erections [29].
3.1.3. Altered contractility of penile smooth muscle by
penile oxygenation
Various investigators have shown that responses of blood
vessels to NO were inhibited at low oxygen tensions [30–
34]. Kim et al. have studied this effect of oxygen tension
on the resistance of the arterial bed of the penis and
on the relaxation of cavernosal trabecular smooth muscle.
They showed that isolated human and rabbit corpus caver-
nosum tissue strips relaxed after addition of endothelium-
dependent dilator acetylcholine and to electrical stimulation
of the autonomic nerves, when bathed in an organ-bath
with arterial-like PO2. These (NO-mediated) responses pro-
gressively were inhibited when PO2 levels where decreased
to levels measured in the deep corpus cavernosum of the
flaccid penis. Restoring PO2 levels to normoxic conditions
restored this endothelium-dependent and neurogenic relax-
ation. Furthermore, they showed that low PO2 reduced basal
levels of cGMP, prevented cGMP accumulation induced by
nerve stimulation, and inhibited cytosolic NOS activity. They
concluded that penile concentration of oxygen modulates
penile erection by regulating NO synthesis in the corpus
cavernosum [35].
3.2. Structural changes following
cavernous neurotomy
A number of patients who have undergone radical prosta-
tectomy complain of subjective penile shortening. Various
clinical studies have addressed this finding, with a reported
incidence of penile shortening of in 9–71% of patients [36–
39]. User et al. showed a loss in penile wet weight in a
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rat model following bilateral neurotomy, although unilateral
neurotomy showed a much greater preservation of penile
weight. The majority of authors suggest that penile fibrosis
accounts for these morphometric changes, by reducing the
extensibility and volume of the corpus cavernosum [40].
Also, denervation-induced apoptosis has been proposed to
play a role in penile shortening after neurotomy [41].Mulhall
recently proposed a hypothesis that penile size reduction
should be divided into early postoperative and reversible
size reduction (hypothised to be due to postoperative sym-
pathetic overdrive), and delayed and permanent structural
changes due to hypoxia and denervation-induced structural
changes [42].
3.2.1. Postoperative early reversible penile size reduction
The hypothesis of Mulhall that early penile size reduction
is the result of sympathetic hyperinnervation is based on
the fact that nerve growth factor (NGF), a neurotrophin
which is released after peripheral nerve damage, induces
differentiation of sympathetic neurons and enhances target
innervation [43, 44]. This mechanism is suspected to induce
sympathetic hyperinnervation of the corpus cavernosum,
following an earlier regeneration of sympathetic nerve fibers,
resulting in smooth muscle contraction and a hypertonic
state of the penis. This hypothesis was supported by a
recently published clinical study of Gontero and colleagues
[39].
3.2.2. Postoperative permanent structural
changes: apoptosis
Klein et al. stated that, given the observation that penile
size may decrease after radical prostatectomy, damage to the
cavernous nerves might result in apoptosis of cells in erectile
tissues of the penis. They found the presence of condensed
and fragmented cell nuclei (characteristic of apoptotic
cells) within the erectile tissue, and expression of sulfated
glycoprotein-2 (a protein found to increase dramatically
in several urogenital tract tissues undergoing apoptosis),
in denervated rat-penises versus a sham-operated control
group [41]. User and colleagues have elucidated the role of
apoptosis in the pathophysiology of postprostatectomy ED
in a postpubertal male Sprague-Dawley rat model. Rats were
randomized to bilateral or unilateral CN transection versus
a sham operation. At different time intervals following the
procedure, penile wet weight, DNA content, and protein
content were measured. Tissue sections of the penis were
stained for apoptosis, and the apoptotic index was calculated.
Finally, staining for endothelial and smooth muscle cells was
done to identify the apoptotic cell line. They found that bilat-
eral cavernous neurotomy induced significant apoptosis. In
addition, it was found that most apoptotic cells were located
just beneath the tunica albuginea where the subtunical
venular plexus is located. Finally the authors demonstrated
that apoptotic cells were predominantly smooth muscle cells
and not endothelial cells [40, 45]. This finding strongly
implies that smooth muscle cells somehow depend on neural
innervation. The programmed cell-death of smooth muscle
has further implications. It has been shown that reductions
in the quantity of smoothmuscle cells is a pivotal event in the
development of veno-occlusive dysfunction, which has been
shown to play a major role in postprostatectomy ED [46, 47].
Sonic hedgehog homolog (SHH) is one of three proteins
in the mammalian hedgehog family. It plays a key role in
regulating vertebrate organogenesis and remains important
in the adult. It controls cell division of adult stem cells.
SHH was suggested to play a role in apoptosis of smooth
muscle cells. In a series of experiments by Podlascek et
al., bilateral CN resection resulted in decreased SHH in
the smooth muscle of the corpora cavernosal sinusoids
and extensive morphological changes, including increased
apoptosis. The SHH cascade acts to establish normal penile
morphology. Nerve injury disrupts the SHH cascade and
corpora cavernosal homeostasis such that morphological
changes in sinusoid structure ensue, resulting in ED. Bond
et al. illustrated that neural activity and a trophic factor
from the pelvic ganglia or cavernous nerves are necessary to
regulate SHH protein and smooth muscle abundance in the
penis [48–51].
3.2.3. Postoperative permanent structural
changes: fibrosis
Leungwattanakij and associates evaluated the isolated effects
of CN injury on cavernous oxygenation and cavernous
fibrosis using the Sprague-Dawley rat. They showed that
production of transforming growth factor-β1 (TGF-β1) and
TGF-β1 mRNA expression as well as collagen I and III
protein expressions was significantly greater in the cavernous
neurotomy-group compared to a sham-operated group [28].
TGF-β1 is associated with increased collagen synthesis by
cavernous smooth muscle cells, resulting in cavernosal
fibrosis. Furthermore, TGF-β1 dependent endothelin-1 (ET-
1) synthesis is increased. ET-1 is a potent constrictor of penile
smooth muscle and a profibrotic peptide [52]. Studies also
showed that low oxygen tension in human cavernosal tissue
inhibits production of PGE1. PGE1 inhibits collagen forma-
tion by inhibiting TGF-β1 that induces collagen synthesis.
With the inhibition of PGE1, TGF-β1 is allowed to induce
connective tissue synthesis [53–59]. Prolonged periods of
cavernosal hypoxia thus lead to increased deposition of
connective tissue that may finally lead to a decrease in penile
distensibility, veno-occlusive dysfunction, ED, and reduction
in penile length.
4. CORPUS CAVERNOSUM OXYGENATION
PRESERVING STRATEGIES
4.1. Intracavernous injections of vasoactive agents
The finding that poor cavernosal oxygenation induces cav-
ernosal structural damage which causes erectile dysfunction
following radical prostatectomy leads to the hypothesis that
preserving the oxygenation of the corpora cavernosa by
improving blood flow might improve erectile dysfunction.
Montorsi et al. conducted a pioneering clinical study on the
effects of intracavernosal injections of aldoprostil early after
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bilateral nerve sparing prostatectomy and saw a significantly
higher recovery of spontaneous erections in treated patients
treated versus observation alone [13].
Preclinical data on the use of intracavernosal and
intraurethral vasoactive agents is limited. Moreland et al.
found that in vitro TGF-β1 mRNA induction was suppressed
by PGE1 via increased levels of cAMP. These data suggest
that prostaglandins and TGF-β1 may play a key role in
modulation of collagen synthesis in the corpus cavernosum,
and in the regulation of fibrosis of the corpus cavernosum
[55–60]. A cross-regulation of intracellular cGMP and cAMP
in cultured human corpus cavernosum smooth muscle cells
was found by Kim et al. They showed a rise in cGMP
(which has been identified as an antifibrotic mediator)
as a response to a rise in intracellular cAMP, which is
accomplished by intracavernous injection of PGE1 [61, 62].
These in vitro observations are likely to play a major role
in the recovery of spontaneous erections in patients treated
with intracavernous PGE1 following nerve sparing radical
prostatectomy.
4.2. PDE-5-inhibitors (PDE5-I)
PDE5-I act within the smoothmuscle cells where the enzyme
phosphodiesterase-5, an enzyme which naturally degrades
cGMP, is inhibited. This causes increased levels of cGMP,
leading to activation of cGMP specific protein kinases which
activate further intracellular events, eventually leading to
reduction of intracellular calcium, being associated with
cavernosal smooth muscle relaxation. The mechanism of
PDE5-I is thus dependent on the production of NO from the
nerve endings, which initiates production of cGMP.
Padma-Nathan and colleagues reported the results of
a randomized, placebo-controlled study examining the
benefits of nightly administration of sildenafil during the
postoperative period following a bilateral nerve-sparing RRP.
This study included 76 men with normal preoperative
erectile function. Forty-eight weeks after bilateral nerve-
sparing RRP, 27% of patients receiving sildenafil demon-
strated return of spontaneous erectile function, compared
with 4% in the placebo group. Postoperative NPT assess-
ments supported these patient-reported results [15]. Since
Padma-Nathan et al. published their results of the clinical
applicability of PDE5-I, preclinical effects of this class of
drugs have been the focus of intense investigation.
Ferrini et al. were the first to demonstrate that long-
term continuous oral administration of a PDE5-I (varde-
nafil) in rats prevents neuropraxia-induced veno-occlusive
dysfunction, presumably as a result of the antifibrotic effects
of PDE5-I and the preservation of the corporal SM mass by
upregulation of SM cell replication [63]. The same group
demonstrated the same antifibrotic effects and prevention of
veno-occlusive dysfunction with the use of the other PDE5-
inhibitors, sildenafil and tadalafil, and showed that these
effects where cGMP mediated, but independent of inducible
NOS (iNOS) upregulation, as they hypothesised in their
vardenafil experiment [62–64]. Vignozzi et al. demonstrated
in vitro that bilateral CN neurotomy induced penile hypoxia
shown by a dramatically increased hypoxyprobe labeling,
a generally accepted probe of hypo-oxygenation after a
3-month interval from surgical neurotomy. They found
that chronic tadalafil treatment almost completely restored
penile oxygenation and smooth muscle/fibrous tissue ratio
at histology [65]. They also found that sildanefil adminis-
tration was able to counteract penile hypoxia, expression
of profibrotic endothelin-1 type B receptor (ETB), and
hypersensitivity to a ETB agonist IRL-1620 (using an in vitro
contractility study), with its effect being more evident the
earlier it was administered [66]. These studies indicate that
PDE5-I can potentially protect and preserve the integrity of
the corpora after cavernosal nerve damage when given on a
long term and continuous basis [67].
At genomic level, the impact of sildanefil treatment on
gene expression in the rat CN injury model was evaluated
by Mu¨ller et al. of the Memorial Sloan-Kettering Cancer
Centre in New York. They used microarray analysis to
elucidate which genes are altered by administration of PDE5-
I in the CN injury model and identified genes that are
altered in the CN injury model and that are restored
towards normal levels with the use of sildenafil. These genes
predominantly belonged to apoptosis, neurotrophism, and
endothelial funtion families [68].
4.3. Hyperbaric oxygen therapy
Hyperbaric oxygen therapy (HBOT) has been used in the
treatment of a variety of medical conditions, in the urol-
ogy field especially for radiation-induced cystitis. Oxygen
hypersaturation has been proven to induce angiogenesis and
enhance wound healing based on the excessive supply of
oxygen. Since hypoxia is assumed to be the capital factor in
inducing penile structural changes and erectile dysfunction
following cavernous nerve injury, Mu¨ller et al. [69] inves-
tigated the effects of hyperbaric oxygen therapy, inducing
hyperoxygenation in this setting. They used a bilateral cav-
ernous nerve crush-injury Sprague-Dawley rat model which
was exposed to ten sessions of hyperbaric oxygen at three
atmospheres for the duration 90 minutes. They measured
ICP after CN stimulation under controlled conditions with
continuous systemic blood pressure measurement, which
according to the authors provides an accurate measurement
of erectile response. They found that rats in the HBOT group
had significantly higher mean ICP/MAP ratios compared
with the untreated group. They demonstrated preservation
of smooth muscle/collagen ratio with HBOT using Masson’s
Trichrome coloring of penile cross-sections. This study
was the first to show a protective effect of HBOT on
erectile function, and literature data is therefore limited
[69]. Theoretically, induction of angiogenesis by HBOT
might potentially accelerate tumor growth in cancer patients
and could therefore be unfavourable in patients treated for
pelvic malignancies. This issue was however studied in a
mouse model that was developed to investigate the effect
of HBOT on prostate cancer cell growth in patients treated
for radiation-induced hemorrhagic cystitis. The investigators
did not witness increased rates of tumor growth, and they
concluded that HBOT in cases of prostate cancer is not
associated with increased oncological risk [70].
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4.4. Nitric oxide donor therapy
Since neuropraxia causes loss of NOS containing nerves
and hypoxia, resulting in a decrease in available NO and
structural changes, Veliev and associates hypothesised that
direct restoration of NO in the penis could prevent these
changes after denervation. This group investigated the effect
of intracorporeal administration of newNO donor dinitrosyl
iron complex in a bilateral CN crush injury group compared
to a sham-operated group and an untreated group CN
crush injury group. They used analysis of mitotic activity
of smooth muscle (decreased after CN injury), endothe-
lium, and fibroblasts (both increased after CN injury) for
evaluation of cavernous fibrosis development and found a
stabilisation of fibroblast proliferation and improvement of
smooth muscle mitotic activity in the group treated with
intracavernosal injections of NO donor [71].
5. NEUROMODULATORY STRATEGIES
During radical prostatectomy, even with the most advanced
nerve-sparing dissection techniques, neuropraxia, stretch-
ing, and axotomy of the cavernous nerves are inevitable.
Although the peripheral nervous system is capable of
endogenous regeneration, this response is limited and usu-
ally does not allow full recovery of nerve function. Cavernous
nerves have been shown to possess the capability to regen-
erate in 6 months. Recently, accumulating evidence suggests
that a return of potency following radical prostatectomy is
partially dependent on regeneration of the cavernous nerves
and axonal regeneration in the remaining neural tissue.
Several treatment strategies to improve this therapeutic
neurogenesis have been under investigation in animal mod-
els, including immunophilin ligands, neurotrophins, growth
factors and, more recently, stem cell therapy [45, 72].
5.1. Immunophilin ligands
Immunophilin ligands cyclosporin A and FK506 (Tacrolimus)
are short polypeptides which block the activation of
lymphocytes and other immune cells. In cells, FK506
and cyclosporine A bind to intracellular proteins called
immunophilins. The formed complex inhibits the activity
of calcineurin, a cellular signaling protein which is one of
the key enzymes regulating the activity of many proteins in
neurons [71]. Immunophilin ligands have been shown to
hold neuroprotective and neuroregenerative potential in the
central nervous system as well as in peripheral nerves. FK506
showed both functional recovery and nerve regeneration
in the sciatic nerve after crush injury in an animal model
[73, 74]. This success brought immunophilin ligands under
interest for the protection of penile innervation following CN
injury. Administration of FK506 orally or intraperitoneally
was found to protect erectile function measured by intracav-
ernous pressure monitoring after electrical stimulation of the
CN following CN injury. Immunohistochemical evaluation
of a CN crush model treated with FK506 showed maintained
peripheral unmyelinated axon integrity and CN architecture
in a bilateral nerve crush injury rat model. The crush injury
was used to simulate the effects of nerve-sparing radical
prostatectomy, where neuropraxia occurs more likely than
neurotomy [75, 76]. FK506 also induced high glutathione
peroxidase expression, an antioxidant enzyme, suggesting
that FK506 promotes erectile recovery through antioxidative
mechanisms [77].
5.2. Nonimmunosuppressant lmmunophilin ligands
There are some concerns about the application of immuno-
suppressant (and carcinogenic) qualities of FK506 therapy
in prostate cancer patients, although daily administration
of a dose of 2-3mg/day in a study by Fleischmann et
al. in humans with rheumatoid arthritis did not induce
immunosuppression [78]. Therefore, the use of nonim-
munosuppressant immunophilin ligands has recently gained
interest of researchers. Nonimmunosuppressant molecules
have recently been developed: GPI1046 by (Guilford Phar-
maceuticals Inc., Md, USA) (now MGI Pharma), FK1706
by (Astellas Pharmaceuticals Inc., Ill, USA). Valentine et
al. studied the effects of GPI1046 administration on CN
integrity and erectile function under various conditions of
CN crush injury. They found that oral or intraperitoneal
administration of GPI1046 preserved intracavernous pres-
sure (ICP) after electrical CN stimulation, compared to
vehicle treated animals. They also evaluated ultrastructural
integrity of the distal CN and found preservation of unmyeli-
nated axons compared to the vehicle-treated group [79].
GPI1406 was shown not to promote prostate cancer cells
in vitro [80]. Bella et al. proved that subcutaneous admin-
istration of FK1706 was effective in enhancing the recovery
of erectile function in a concentration-dependent manner.
With a high-dose treatment group showing significantly
increased ICP compared to the vehicle-treated group in
response to electrical CN stimulation. Sham treated animals
showed regular axon sizes and shapes with homogenous
GAP-43 and neurofilament staining, whereas injured axons
showed irregular shapes, sizes, and staining patterns. FK1706
treatment restored axon shape and staining patterns. Injury
significantly decreased nicotinamide adenine dinucleotide
phosphate staining and FK1706 treatment showed a trend
toward increased staining [81, 82].
5.3. Neurotrophins and growth factors
The effect of growth factors on erectile recovery and nerve
regeneration has been extensively studied by Lue’s group at
the Knuppe Laboratory for Molecular Urology in San Fran-
sisco. They previously reported enhanced NOS-containing
nerve fiber regeneration after injury, using injections of
systemic growth hormone (GH) and insulin-like growth
factor-1 (IGF-1). However, some obvious concerns are
existing about the systemic use of growth factors in patients
treated for malignancy.
5.3.1. Brain derived neurotrophic factor
Neurotrophins are proteins that enhance neuronal regenera-
tion and survival of specific neuronal populations through
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a variety of signaling pathways [77]. Brain derived neu-
rotrophic factor (BDNF) has been the focus of intense
investigation because of the central role it plays in neuronal
development, maturation, and survival after injury [72]. It is
part of the family of growth factors that includes NGF and
neurotrophin-3, -4, and -5. It has demonstrable retrograde
axonal transport, which occurs asmolecules that are taken up
by the neural synapses at the corpus cavernosum and travel
retrograde to the cell body in the major pelvic ganglion to
induce their neuroregenerative effects. This characteristic of
BDNF makes it a suitable molecule for intracavernous injec-
tion. Lue’s group demonstrated that intracavernous injection
of adeno-associated virus-BDNF prevents the degeneration
of neuronal NOS containing neurons in the major pelvic
ganglion and facilitated regeneration of NOS containing
nerve fibers in penile tissue, thus enhancing erectile recovery
following bilateral CN injury. They identified the JAK/STAT
pathway as primary mechanism for in vitro BDNF-mediated
neurite outgrowth. They also demonstrated a synergistic
effect of BDNF when combined with vascular endothelial
growth factor (VEGF) on neural and erectile recovery [83].
5.3.2. Glial cell-line derived neurotrophic factors
Glial cell-line derived neurotrophic factors (GDNFs) are a
novel group of neuroregenerative molecules of which the
most studied are GDNF and neurturin (NRTN). Studies
performed by Leitner et al. and Laurikainen et al. showed
retrograde axonal transport of NRTN when injected in the
penile shaft and suggested an effect of NRTN as a target-
derived neuritogenic factor for postganglionic neurons via a
system mediated by the GDNF receptor family, mainly the
GDNF-α2 receptor [72, 84, 85]. In vivo, NRTN was able to
preserve erectile function 5 weeks after nerve crush injury
when applied to the site of nerve injury compared to a
control group where albumin was applied locally, with an
ICP increase of 55% compared to the control group [86].
5.3.3. Growth differentiation factor 5
Growth differentiation factor-5 (GDF-5) is a recently isolated
neurotrophic factor which belongs to the TGF-β super-
family, which was previously proven to be a neurotrophic
and neuroprotective factor on dopaminergic neurons after
intracerebral injection in vitro and in vivo. Data concerning
the peripheral nervous system is limited to sensory neu-
rons. Fandel et al. [87] investigated the in vivo effects of
implantation of a GDF-5 impregnated sponge in the corpus
cavernosum of a rat CN crush injury model. They found that
intracavernosal application of GDF-5 enhanced the recovery
of erectile function and preservation of n-NOS containing
nerve fibers, with a low-dose application giving the most
promising results [87].
5.3.4. Erythropoietin
Erythropoietin (Epo) was originally known for the erythro-
poiesis. It is has now become evident that Epo is a multi-
functional trophic factor. Epo for example has potent
neurotrophic activity on a variety of neural cells and
includes prevention of cell death and induction of neu-
ronal differentiation. Campana and Myers demonstrated
the production of Epo and Epo receptors in cells of the
peripheral nerve system [88]. This group proposed a model
in which Schwann cells are a major target for Epo in
injured peripheral nerves, and stated that Epo-receptor-
induced cell signaling and Schwann cell proliferation may
protect injured peripheral nerves and promote regeneration
[89]. Allaf et al. were the first to show expression of Epo
receptor in neuronal cell bodies of the major pelvic ganglion,
penile nerves, and endothelial cells in the penis, and more
recently, in the periprostatic neurovascular bundles [90,
91]. They investigated the potential benefits of Epo on
erectile recovery following cavernous nerve injury, and found
significantly greater maximal intracavernous pressure area
under the curve normalized to mean arterial pressure in
EPO treated versus saline treated animals. Morphologically,
electron microscopy revealed significant improvement in
axonal regeneration in rhEPO treated animals 14 days
following injury compared to controls [90].
5.4. Stem cell therapy
Although the number is still limited, some studies on
stem cell therapy for erectile dysfunction have recently
been conducted. Human mesenchymal stem cells (B10) and
neural crest stem cells (K10), transplanted via a retroviral
vector into the rat corpus cavernosum, have been shown to
posess the ability to differentiate into smooth muscle cells
or endothelial cells [92, 93]. Damage to smooth muscle and
endothelium plays a major role in the development of veno-
occlusive dysfunction and ED following radical prostatec-
tomy. Therefore B10 and K10 cells may be an ideal cell source
for reconstructing endothelial and smooth muscle cells in
the corpus cavernosum in cell therapy for neurogenic ED.
Bochinski et al. used embryonic stem cells that differentiated
along the neuronal cell line, which they injected into the
corpus cavernosum of a rat bilateral CN crush injury model.
They measured a markedly increased ICP upon electrical
CN stimulation compared to controls, and a greater degree
of neuroregeneration of n-NOS containing nerve fibers in
the stem cell treatment group [94]. Bella et al. were able
to demonstrate in vitro neurite outgrowth from the major
pelvic ganglion of the rat induced by adult adipose tissue-
derived stem cells, which were not induced towards a specific
neuronal cell line prior to administration [95].
6. CONCLUSION
Although nerve-sparing techniques are rapidly emerging, ED
following radical prostatectomy remains amajor problem for
the prostate cancer patient and his urologist. Disease-free
survival remains the primary goal of radical prostatectomy,
although since patients are increasingly younger at the time
of diagnosis and treatment, more attention is being paid to
quality of life issues. The underlying mechanisms leading
to ED have been elucidated by various research institutes.
These insights have led to the use of intracavernosal
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vasoactive substances and more recently, oral PDE5-I on
a daily basis in patients that develop ED. Currently, no
prophylactic treatment is administered at the time of CN
injury. The benefits of these therapeutic modalities have been
demonstrated in preclinical as well as in clinical studies.
More recently, however, the focus of research has been on
the effects of neuromodulatory molecules and stem cell
therapy. Until now, this new class of agents has only been
shown to be effective in reclinical experiments, although FDA
approval has been given for the use of nonimmunosupres-
sant immunophilin ligands. Stem cell therapy is however still
experimental. The increasing insights in mechanisms behind
ED following radical prostatectomy and the identification
of novel substances that promote CN recovery may lead to
a new spectrum of treatment modalities for ED following
radical prostatectomy.
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